This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Incyte's Management Presents At Goldman Sachs Healthcare Conference (Transcript)

Incyte Corporation (INCY)

Goldman Sachs Healthcare Conference Call

June 06, 2012 06:20 pm ET

Executives

Pat Andrews - EVP & Chief Commercial Officer

Pam Murphy - VP, IR & Corporate Communications

Analysts

Sapna Srivastava - Goldman Sachs

Yogesh Ahuja - Goldman Sachs

Presentation

Sapna Srivastava - Goldman Sachs

Good afternoon. Thanks for waiting up; I am Sapna Srivastava; I am Biotech Analyst at Goldman Sachs and it’s my pleasure to host Pat Andrews and Pam Murphy from Incyte. Pat is really responsible as the Chief Commercial Officer and Pam is the Investor Relations entity. So you know we really want to kick this off. I just want to remind the audience that this is meant to be interactive and we want you to ask a lot of questions and keep it as interactive as possible and I am just going to kick it off with like you know really topical and really good news that we saw this morning which is the RA data and while all of us were expecting to see tomorrow, we are really pleased that it came today and we have the opportunity to discuss that at this forum.

So I am going to just start it off with like may be recapping it for the audience who did not necessarily have a chance to see the data and also just to help us understand like how you view the profile of the drug with more visibility on it?

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs